At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 162 enrolled
Drug / intervention
Fluarix™ +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Immunogenicity and Safety Study of GSK Biologicals' Seasonal (2010-2011) Influenza Vaccine Fluarix™ in Children Previously Vaccinated With GSK Biologicals' H1N1 Vaccine Pandemrix™
In Brief
A Phase 4 clinical trial evaluating Fluarix™ and Havrix™ Junior for Influenza. Completed, enrolled 162 participants across 7 sites in 2 countries.
Detailed Summary
This study is designed to assess the immunogenicity, reactogenicity and safety following vaccination with GSK Biologicals' Fluarix vaccine in children who have previously been vaccinated with two doses of Pandemrix at the age of 6 months-9 years.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesNetherlands, Sweden
Collaborators--
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2010
Enrollment StartSep 2010
Primary CompletionMay 2011
TodayJul 2026
First PostedSep 8, 2010
Enrollment StartSep 15, 2010
Primary CompletionMay 26, 2011
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 15.8 years ago
Interventions
Fluarix™biological
One or two intramuscular injections
Havrix™ Juniorbiological
Two intramuscular injections